1. Home
  2. CLRB vs SNGX Comparison

CLRB vs SNGX Comparison

Compare CLRB & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cellectar Biosciences Inc.

CLRB

Cellectar Biosciences Inc.

HOLD

Current Price

$3.39

Market Cap

12.8M

Sector

Health Care

ML Signal

HOLD

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$1.59

Market Cap

13.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLRB
SNGX
Founded
2002
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.8M
13.8M
IPO Year
N/A
1987

Fundamental Metrics

Financial Performance
Metric
CLRB
SNGX
Price
$3.39
$1.59
Analyst Decision
Hold
Strong Buy
Analyst Count
2
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
54.5K
304.6K
Earning Date
11-13-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.71
$1.09
52 Week High
$20.60
$6.23

Technical Indicators

Market Signals
Indicator
CLRB
SNGX
Relative Strength Index (RSI) 42.79 54.55
Support Level $3.30 $1.56
Resistance Level $3.15 $1.70
Average True Range (ATR) 0.30 0.11
MACD 0.04 0.02
Stochastic Oscillator 38.25 71.64

Price Performance

Historical Comparison
CLRB
SNGX

About CLRB Cellectar Biosciences Inc.

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: